Signadori Bio, a preclinical-stage biopharmaceutical company developing a next generation, off-the shelf, in vivo engineered, monocyte immunotherapy platform to treat solid tumors, has appointed Dr. Selwyn Ho as Chief Executive Officer.

Ho is an experienced biopharma and biotech executive, with nearly 30 years of experience across commercialization, drug development and multiple pre-& post-product launches, with a focus in ophthalmology, immunology and immuno-oncology, leveraging cell therapy, monoclonal antibodies and multi-specific antibody modalities.

“Selwyn’s appointment marks an important milestone for Signadori Bio, and we warmly welcome him to the team. As co-founders, we remain deeply committed to the scientific vision that underpins our platform, harnessing the immune potential of gene-modified monocytes to address unmet needs in solid tumor treatment. We are confident that Selwyn’s expertise will accelerate our path to the clinic,” said Dr. Jean-Luc Perfettini and Professor Nathalie Chaput, Co-founders, Signadori Bio.

Experience

Most recently, Ho was Chief Executive Officer of Medigene AG, a German immuno-oncology company developing T cell receptor (TCR) guided modalities for the treatment of solid tumors. At Medigene, he led the strategic pivot into the development of off-the shelf treatments, whilst advancing the lead autologous cell therapy program into a successful IND and CTA approval. Prior to this, Ho was EVP, Chief Business Officer at Connect Biopharma, a U.S., immunology focused biotech, where he supported the successful crossover financing, subsequent upsized, over-subscribed IPO, and the build out of the company’s U.S. operations and footprint.

“I am excited for the significant potential of our unique approach, supported by promising early pre-clinical data,” Ho remarked. “I look forward to working closely with Matthieu Coutet, Sofinnova Partners, our investors, and our co-founders Dr. Jean-Luc Perfettini and Prof. Nathalie Chaput-Gras as well as building on the excellent research from Gustave-Roussy, together with our team of dedicated scientists, to advance the company toward its next set of milestones.”